These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 32870526)

  • 21. MUTYH is associated with hepatocarcinogenesis in a non-alcoholic steatohepatitis mouse model.
    Sakamoto H; Miyanishi K; Tanaka S; Ito R; Hamaguchi K; Sakurada A; Sato M; Kubo T; Osuga T; Murase K; Takada K; Nakabeppu Y; Kobune M; Kato J
    Sci Rep; 2021 Feb; 11(1):3599. PubMed ID: 33574380
    [TBL] [Abstract][Full Text] [Related]  

  • 22. MicroRNA expression analysis in high fat diet-induced NAFLD-NASH-HCC progression: study on C57BL/6J mice.
    Tessitore A; Cicciarelli G; Del Vecchio F; Gaggiano A; Verzella D; Fischietti M; Mastroiaco V; Vetuschi A; Sferra R; Barnabei R; Capece D; Zazzeroni F; Alesse E
    BMC Cancer; 2016 Jan; 16():3. PubMed ID: 26728044
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Imbalance in ALR ubiquitination accelerates the progression of nonalcoholic steatohepatitis to hepatocellular carcinoma.
    Zheng M; Ai Z; Guo Y; Chen Y; Xie P; An W
    Oncogene; 2023 Jan; 42(4):308-321. PubMed ID: 36434180
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Nonalcoholic Steatohepatitis and HCC in a Hyperphagic Mouse Accelerated by Western Diet.
    Ganguly S; Muench GA; Shang L; Rosenthal SB; Rahman G; Wang R; Wang Y; Kwon HC; Diomino AM; Kisseleva T; Soorosh P; Hosseini M; Knight R; Schnabl B; Brenner DA; Dhar D
    Cell Mol Gastroenterol Hepatol; 2021; 12(3):891-920. PubMed ID: 34062281
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A short-term rodent model for non-alcoholic steatohepatitis induced by a high-fat diet and carbon tetrachloride.
    Araujo LCC; Dias CCB; Sucupira FG; Ramalho LNZ; Camporez JP
    Biosci Rep; 2024 May; 44(5):. PubMed ID: 38660995
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A Cholecystokinin Receptor Antagonist Halts Nonalcoholic Steatohepatitis and Prevents Hepatocellular Carcinoma.
    Tucker RD; Ciofoaia V; Nadella S; Gay MD; Cao H; Huber M; Safronenka A; Shivapurkar N; Kallakury B; Kruger AJ; Kroemer AHK; Smith JP
    Dig Dis Sci; 2020 Jan; 65(1):189-203. PubMed ID: 31297627
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The SGLT2 Inhibitor Canagliflozin Prevents Carcinogenesis in a Mouse Model of Diabetes and Non-Alcoholic Steatohepatitis-Related Hepatocarcinogenesis: Association with SGLT2 Expression in Hepatocellular Carcinoma.
    Jojima T; Wakamatsu S; Kase M; Iijima T; Maejima Y; Shimomura K; Kogai T; Tomaru T; Usui I; Aso Y
    Int J Mol Sci; 2019 Oct; 20(20):. PubMed ID: 31652578
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Myeloid-specific IRE1alpha deletion reduces tumour development in a diabetic, non-alcoholic steatohepatitis-induced hepatocellular carcinoma mouse model.
    Van Campenhout S; Tilleman L; Lefere S; Vandierendonck A; Raevens S; Verhelst X; Geerts A; Van Nieuwerburgh F; Van Vlierberghe H; Devisscher L
    Metabolism; 2020 Jun; 107():154220. PubMed ID: 32243868
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Silencing of microRNA-122 is an early event during hepatocarcinogenesis from non-alcoholic steatohepatitis.
    Takaki Y; Saito Y; Takasugi A; Toshimitsu K; Yamada S; Muramatsu T; Kimura M; Sugiyama K; Suzuki H; Arai E; Ojima H; Kanai Y; Saito H
    Cancer Sci; 2014 Oct; 105(10):1254-60. PubMed ID: 25117675
    [TBL] [Abstract][Full Text] [Related]  

  • 30. STARD1 promotes NASH-driven HCC by sustaining the generation of bile acids through the alternative mitochondrial pathway.
    Conde de la Rosa L; Garcia-Ruiz C; Vallejo C; Baulies A; Nuñez S; Monte MJ; Marin JJG; Baila-Rueda L; Cenarro A; Civeira F; Fuster J; Garcia-Valdecasas JC; Ferrer J; Karin M; Ribas V; Fernandez-Checa JC
    J Hepatol; 2021 Jun; 74(6):1429-1441. PubMed ID: 33515644
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Analysis of amino acid profiles of blood over time and biomarkers associated with non-alcoholic steatohepatitis in STAM mice.
    Iida A; Kuranuki S; Yamamoto R; Uchida M; Ohta M; Ichimura M; Tsuneyama K; Masaki T; Seike M; Nakamura T
    Exp Anim; 2019 Nov; 68(4):417-428. PubMed ID: 31155606
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lipid-lowering agents inhibit hepatic steatosis in a non-alcoholic steatohepatitis-derived hepatocellular carcinoma mouse model.
    Orime K; Shirakawa J; Togashi Y; Tajima K; Inoue H; Nagashima Y; Terauchi Y
    Eur J Pharmacol; 2016 Feb; 772():22-32. PubMed ID: 26724391
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Peretinoin, an acyclic retinoid, suppresses steatohepatitis and tumorigenesis by activating autophagy in mice fed an atherogenic high-fat diet.
    Okada H; Takabatake R; Honda M; Takegoshi K; Yamashita T; Nakamura M; Shirasaki T; Sakai Y; Shimakami T; Nagata N; Takamura T; Tanaka T; Kaneko S
    Oncotarget; 2017 Jun; 8(25):39978-39993. PubMed ID: 28591717
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A new preclinical model of western diet-induced progression of non-alcoholic steatohepatitis to hepatocellular carcinoma.
    Green CD; Weigel C; Brown RDR; Bedossa P; Dozmorov M; Sanyal AJ; Spiegel S
    FASEB J; 2022 Jul; 36(7):e22372. PubMed ID: 35639028
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Increased hepatic oxidative DNA damage in patients with nonalcoholic steatohepatitis who develop hepatocellular carcinoma.
    Tanaka S; Miyanishi K; Kobune M; Kawano Y; Hoki T; Kubo T; Hayashi T; Sato T; Sato Y; Takimoto R; Kato J
    J Gastroenterol; 2013 Nov; 48(11):1249-58. PubMed ID: 23329365
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of murine steatohepatitis models identifies a dietary intervention with robust fibrosis, ductular reaction, and rapid progression to cirrhosis and cancer.
    Wei G; An P; Vaid KA; Nasser I; Huang P; Tan L; Zhao S; Schuppan D; Popov YV
    Am J Physiol Gastrointest Liver Physiol; 2020 Jan; 318(1):G174-G188. PubMed ID: 31630534
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Preclinical Models for Studying NASH-Driven HCC: How Useful Are They?
    Febbraio MA; Reibe S; Shalapour S; Ooi GJ; Watt MJ; Karin M
    Cell Metab; 2019 Jan; 29(1):18-26. PubMed ID: 30449681
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fucoxanthin inhibits hepatic oxidative stress, inflammation, and fibrosis in diet-induced nonalcoholic steatohepatitis model mice.
    Takatani N; Kono Y; Beppu F; Okamatsu-Ogura Y; Yamano Y; Miyashita K; Hosokawa M
    Biochem Biophys Res Commun; 2020 Jul; 528(2):305-310. PubMed ID: 32475638
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Activation of the NLRP3 inflammasome by CCl
    Vargas-Pozada EE; Ramos-Tovar E; Rodriguez-Callejas JD; Cardoso-Lezama I; Galindo-Gómez S; Gil-Becerril K; Vásquez-Garzón VR; Arellanes-Robledo J; Tsutsumi V; Villa-Treviño S; Muriel P
    Ann Hepatol; 2023; 28(1):100780. PubMed ID: 36309184
    [TBL] [Abstract][Full Text] [Related]  

  • 40. MicroRNA-223 Ameliorates Nonalcoholic Steatohepatitis and Cancer by Targeting Multiple Inflammatory and Oncogenic Genes in Hepatocytes.
    He Y; Hwang S; Cai Y; Kim SJ; Xu M; Yang D; Guillot A; Feng D; Seo W; Hou X; Gao B
    Hepatology; 2019 Oct; 70(4):1150-1167. PubMed ID: 30964207
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.